Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early-stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short- and long-term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit and which are not.

Researchers from the Technion—Israel Institute of Technology, together with collaborators from leading medical centers in the United States and Europe, have developed an artificial intelligence (AI) model that predicts both the risk of breast cancer recurrence and the likelihood that a patient will benefit from chemotherapy. The model analyzes routine pathology slides taken at diagnosis, offering a fast, widely accessible alternative to costly genomic tests.